Drug Information

Drug General Information
Drug ID
D0A5EF
Former ID
DCL000831
Drug Name
GW-427353
Drug Type
Small molecular drug
Indication Urinary incontinence [ICD9: 788.3; ICD10:N39.3, N39.4, R32] Phase 2 [521908]
Company
GSK
Structure
Download
2D MOL

3D MOL
Formula
C23H24Cl2N2O3
Canonical SMILES
C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNCC(C3=CC(=CC=C3)C<br />l)O.Cl
InChI
1S/C23H23ClN2O3.ClH/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29;/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29);1H/t22-;/m0./s1
InChIKey
PMXCGBVBIRYFPR-FTBISJDPSA-N
CAS Number
CAS 451470-34-1
PubChem Compound ID
10297443
PubChem Substance ID
15304131, 22671894, 35614758, 47207540, 53643480, 134339299, 135199379, 160682151, 198936207, 223791527, 226872177
Target and Pathway
Target(s) Beta-3 adrenergic receptor Target Info Agonist [536122]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Salivary secretion
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta3 adrenergic receptor signaling pathway
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 521908ClinicalTrials.gov (NCT00394186) A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS). U.S. National Institutes of Health.
Ref 536122Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.